Priority Review awarded to Xtandi for prostate cancer
Back in February, the companies revealed results from the Phase III ARCHES trial in men with mHSPC.
Read More
Author: Anna Smith
Fiasp approved for children in Europe
Novo Nordisk submitted label updates in March this year.
Read More
NICE chief executive to step down
Sir Andrew Dillon has led the organisation for 20 years.
Read More
Skyrizi bags NICE fast-track
Eligible patients in England and Wales will have access to the drug almost two months earlier.
Read More
GSK HIV combo meets main goal in Phase III study
The drug could now be administered every eight weeks compared to every four.
Read More- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
